Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting p85β condensates by RNA therapy inhibits liver cancer progression

ABSTRACT: Targeting p85β condensates by RNA therapy inhibits liver cancer progression

PROVIDER: PRJNA1232683 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32591542_1.fastq.gz	Fastqsanger.gz
	SRR32591542_2.fastq.gz	Fastqsanger.gz
	SRR32591543_1.fastq.gz	Fastqsanger.gz
	SRR32591543_2.fastq.gz	Fastqsanger.gz
	SRR32591544_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Targeting p85β condensates by RNA therapy inhibits liver cancer progression

Project description:PI3K complex consists of catalytic subunit p110s and regulatory subunit p85s. Emerging evidence indicates that p110-free p85 subunits play pivotal roles in diverse biological processes, including cancer progression. In this study, we demonstrate the oncogenic function and underlying mechanism of p110-free p85β in hepatocellular carcinoma (HCC) development. PIK3R2/p85β is highly expressed in HCC tissues and correlates with worse overall survival of HCC patients. Nuclear p85β, but not its cytoplasmic counterpart, exhibits oncogenic activity. In the nucleus of HCC cells, p85β undergoes liquid-liquid phase separation (LLPS) and specifically accumulates in the fibrillar centers of nucleoli, where it drives HCC progression. Within the nucleolar compartment, p85β directly interacts with and stabilizes POLR1A, the catalytic core subunit of RNA polymerase I, thereby enhancing rRNA biosynthesis and maintaining HCC stemness. Furthermore, we develop an engineered circular RNA that encodes a peptide containing p110α ABD domain, which effectively suppresses HCC tumor growth by simultaneously disrupting p85β/POLR1A condensates and inhibiting PI3K/AKT signaling pathway. Our findings not only elucidate the critical role of p85β biomolecular condensates in HCC tumorigenesis but also establish a novel RNA-based therapeutic strategy for HCC intervention.

2025-05-01 | GSE291263 | GEO

miR-193 inhibits bladder cancer progression by targeting N-myc

Project description:miR-193 inhibits bladder cancer progression by targeting N-myc

| PRJNA691550 | ENA

MicroRNA-592 inhibits the progression of breast cancer through targeting CYP20A1

Project description:MicroRNA-592 inhibits the progression of breast cancer through targeting CYP20A1

| PRJNA763812 | ENA

Targeting Cancer Associated Fibroblasts/Tumor Cells Cross-Talk Inhibits Intrahepatic Cholangiocarcinoma Progression

Project description:Targeting Cancer Associated Fibroblasts/Tumor Cells Cross-Talk Inhibits Intrahepatic Cholangiocarcinoma Progression

| PRJNA1143581 | ENA

Light induced targeting enables proteomics on endogenous condensates

Project description:Endogenous condensates with transient constituents are notoriously difficult to study with common biological assays like mass-spectrometry and other proteomics profiling. Here we report a method for light-induced targeting of endogenous condensates (LiTEC) in living cells. LiTEC combines the identification of molecular zip codes that target the endogenous condensates with optogenetics to enable controlled and reversible partitioning of an arbitrary cargo, such as enzymes commonly used in proteomics, into the condensate in a blue light dependent manner. We demonstrate a proof of concept by combining LiTEC with proximity-based biotinylation (BioID) and uncover putative components of transcriptional condensates in mouse embryonic stem cells. Our approach opens the road to genome-wide functional studies of endogenous condensates.

2024-10-18 | GSE270770 | GEO

Light induced targeting enables proteomics on endogenous condensates

Project description:Light induced targeting enables proteomics on endogenous condensates

| PRJNA1128148 | ENA

Fasting Mimic Diet Inhibits Tumor Progression by Targeting IgA+ Cells in Colorectal Cancer

Project description:Fasting Mimic Diet Inhibits Tumor Progression by Targeting IgA+ Cells in Colorectal Cancer

| PRJNA878254 | ENA

Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1

Project description:Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1

| PRJNA1123290 | ENA